The Recall Desk
HighFDA (Drugs)·D-0828-2022·Announced 2022-05-04

FDA recalls NAD+ powder due to failed reconstitution

Olympia Compounding Pharmacy is recalling NAD+ powder vials nationwide because they fail to reconstitute properly. Affected lot F41116 has a beyond-use date of 6/16/2022.

What this means for you

Real risk of harm even if no illness or injury has been reported yet. Stop using the product and follow the agency's guidance.

Our severity reasoning: FDA classified this as Class II, indicating a serious adverse health consequence is possible. Failed reconstitution prevents proper preparation and use of the medication, constituting a risk-of-harm product. No illnesses or injuries are reported.

Plain-English summary

Olympia Compounding Pharmacy is recalling NAD+ Nicotinamide Adenine Dinucleotide lyophilized powder for reconstitution distributed nationwide. The product is supplied as a 500 mg multi-dose vial.

The manufacturer initiated the recall due to failed reconstitution time. The specific lot affected is F41116, which has a beyond-use date of 6/16/2022.

Healthcare providers and patients who received vials from this lot should contact their dispensing pharmacy or healthcare provider regarding this recall.

The recalled product

Product
NAD+ Nicotinamide Adenine Dinucleotide Lyophilized powder for reconstitution, Multi-Dose 500 mg Per Vial, Rx Only, Olympia Pharmaceuticals 6700 Conroy Rd., Ste. 155, Orlando, FL 32835. NDC 73198-0083-00
Manufacturer
Olympia Compounding Pharmacy dba Olympia Pharmacy
Category
Drug — Compounded Injectable
Hazard
  • reconstitution-failure

Is your product affected?

Check your packaging against the codes below. If any of them match, the product is part of this recall.

Lot numbers (1)

  • Lot: F41116 BUD: 6/16/2022

Distribution

Distributed nationwide across the United States.

Related recalls

Same category